WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) is poised to present significant findings on imdusiran, its RNAi therapeutic, during the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2024. The conference, which will take place from November 15-19 in San Diego, CA, will feature four poster presentations from Arbutus, including two late-breaking posters from the IM-PROVE I and II Phase 2a trials.
The first presentation, titled “Soluble Immune Biomarker Profiling of Chronic Hepatitis B Subjects Treated with Imdusiran in Combination with Pegylated Interferon (IFN) Alfa Reveals Phases of Immune Activation,” will be delivered by Emily Thi, Senior Director of Immunobiology and Biomarkers Research at Arbutus Biopharma. Scheduled for November 15 from 8:00 am to 5:00 pm PT, this presentation will highlight how imdusiran, combined with IFN, affects immune biomarkers. Notably, it details phases of Th1 immune activation and inflammation regulation, correlating with a plateau in HBsAg reduction and eventual seroconversion.
Another crucial study, “HBV Target Site for the RNA Interference Therapeutic Imdusiran is Highly Conserved in Chronic Hepatitis B Subjects,” also presented by Emily Thi, will explore the consistency of the imdusiran target site in chronic hepatitis B subjects. The findings reveal that imdusiran retains its efficacy across various HBV genotypes, including A-E, suggesting that specific genetic variations do not affect treatment outcomes.
These presentations highlight the potential of imdusiran as a transformative treatment for hepatitis B. Arbutus Biopharma intends to make the poster presentations available on its website on November 15. Through such research, the company reaffirms its commitment to advancing treatments for liver diseases, providing new hope for patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.